The CADET HR Study group of principal investigators are given in the Appendix.
Heartburn-dominant, uninvestigated dyspepsia: a comparison of ‘PPI-start’ and ‘H2-RA-start’ management strategies in primary care – the CADET-HR Study
Version of Record online: 9 MAY 2005
Alimentary Pharmacology & Therapeutics
Volume 21, Issue 10, pages 1189–1202, May 2005
How to Cite
Armstrong, D., Veldhuyzen van Zanten, S. J. O., Barkun, A. N., Chiba, N., Thomson, A. B. R., Smyth, S., Sinclair, P., Chakraborty, B., White, R. J. and The CADET-HR Study Group (2005), Heartburn-dominant, uninvestigated dyspepsia: a comparison of ‘PPI-start’ and ‘H2-RA-start’ management strategies in primary care – the CADET-HR Study. Alimentary Pharmacology & Therapeutics, 21: 1189–1202. doi: 10.1111/j.1365-2036.2005.02466.x
- Issue online: 9 MAY 2005
- Version of Record online: 9 MAY 2005
- Accepted for publication 20 March 2005
- 2Diagnostic significance, provocants and time-course of heartburn and regurgitation. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 3): S21–3..
- 11Canadian Pantoprazole GERD Study Group. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 2849–57., , , ,
- 12Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997; 11: 755–63., , , et al.
- 15Antisecretory therapy in 1017 patients with ulcer-like or reflux-like dyspepsia in general practice. Eur J Gen Pract 1997; 3: 125–30., .
- 17The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) study. Aliment Pharmacol Ther 2003; 17: 1481–91., , , et al.
- 18An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. CMAJ 2000; 162(Suppl. 12): S1–23., , , et al.
- 20Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23: 998–1017., , .
- 23and contributing participants. The second Canadian consensus conference on the management of patients with gastroesophageal reflux disease. Can J Gastroenterol 1997; 11(Suppl. B): 7B–20B., , , ,
- 28A double-blind randomised controlled trial comparing omeprazole, ranitidine, cisapride and placebo in 512 Helicobacter pylori (Hp) negative primary care patients with uninvestigated dyspepsia (UD) – the CADET HN study. Can J Gastroenterol 2002; 16(Suppl. A): A5., , , et al.
- 29The responsiveness of the Global Overall Symptom (GOS) score – a 7-point Likert scale for the measurement of dyspepsia symptoms in clinical trials. Can J Gastroenterol 2003; 17(Suppl. A): 113A., , , et al.
- 30Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg 1998; 583: 41–9., , , et al.
- 33On demand therapy for heartburn-dominant uninvestigated dyspepsia in primary care practice: the CADET-HR study. Can J Gastroenterol 2003; 17(Suppl. A): 105A., , , et al.
- 45Frequent heartburn symptoms should not be ignored in subjects who self-treat with antacids. Gastroenterology 1996; 110: A241., , , et al.
- 48Symptom status as a surrogate for absence of endoscopic oesophagitis. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 3): S76–8..
- 49Short-term treatment of gastroesophageal reflux disease. A systematic review and meta-analysis of the effect of acid-suppressant drugs in empirical treatment and in endoscopy-negative patients. J Gen Intern Med 2003; 18: 755–63., , , , , .
- 54Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration. Value in Health 2003; 6: 522–31., , , et al.
- 59Factors predicting response to omeprazole treatment in patients with functional dyspepsia. Gastroenterology 1996; 110: A76., , , et al.